| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SART1 |
| Uniprot No | O43290 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-800 aa |
| 活性数据 | MGSSKKHRGE KEAAGTTAAA GTGGATEQPP RHREHKKHKH RSGGSGGSGG ERRKRSRERG GERGSGRRGA EAEARSSTHG RERSQAEPSE RRVKREKRDD GYEAAASSKT SSGDASSLSI EETNKLRAKL GLKPLEVNAI KKEAGTKEEP VTADVINPMA LRQREELREK LAAAKEKRLL NQKLGKIKTL GEDDPWLDDT AAWIERSRQL QKEKDLAEKR AKLLEEMDQE FGVSTLVEEE FGQRRQDLYS ARDLQGLTVE HAIDSFREGE TMILTLKDKG VLQEEEDVLV NVNLVDKERA EKNVELRKKK PDYLPYAEDE SVDDLAQQKP RSILSKYDEE LEGERPHSFR LEQGGTADGL RERELEEIRA KLRLQAQSLS TVGPRLASEY LTPEEMVTFK KTKRRVKKIR KKEKEVVVRA DDLLPLGDQT QDGDFGSRLR GRGRRRVSEV EEEKEPVPQP LPSDDTRVEN MDISDEEEGG APPPGSPQVL EEDEAELELQ KQLEKGRRLR QLQQLQQLRD SGEKVVEIVK KLESRQRGWE EDEDPERKGA IVFNATSEFC RTLGEIPTYG LAGNREEQEE LMDFERDEER SANGGSESDG EENIGWSTVN LDEEKQQQDF SASSTTILDE EPIVNRGLAA ALLLCQNKGL LETTVQKVAR VKAPNKSLPS AVYCIEDKMA IDDKYSRREE YRGFTQDFKE KDGYKPDVKI EYVDETGRKL TPKEAFRQLS HRFHGKGSGK MKTERRMKKL DEEALLKKMS SSDTPLGTVA LLQEKQKAQK TPYIVLSGSG KSMNANTITK |
| 分子量 | 90.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SART1蛋白的3篇参考文献概览，涵盖其在癌症免疫治疗和抗原功能研究中的应用：
---
1. **文献名称**: *"SART1-Derived Epitopes as Potential Targets for Cancer Immunotherapy"*
**作者**: Kikuchi M, et al.
**摘要**: 研究鉴定了SART1蛋白的HLA-A24限制性表位，体外实验证明其可激活细胞毒性T细胞，抑制肿瘤生长，提示其作为癌症疫苗的潜力。
2. **文献名称**: *"Recombinant SART1 Protein Enhances Antigen Presentation in Dendritic Cells"*
**作者**: Yoshida K, et al.
**摘要**: 通过大肠杆菌表达重组SART1.实验证明该蛋白可被树突状细胞摄取并有效呈递，诱导CD8+ T细胞应答，为免疫佐剂开发提供依据。
3. **文献名称**: *"Cloning and Characterization of Human SART1 Gene: Implications for mRNA Splicing Regulation"*
**作者**: Nakashima T, et al.
**摘要**: 报道了SART1基因的克隆及重组蛋白制备，发现其通过调控mRNA剪接影响肿瘤细胞周期，揭示其非免疫相关的分子机制。
---
**备注**：上述文献为示例性质，实际引用需以具体研究为准。若需获取真实文献，建议通过PubMed输入关键词"SART1 recombinant protein"检索近年论文。部分早期关键研究发表于1990s-2000s的《Cancer Research》《Journal of Immunology》等期刊。
SART1 (Squamous Cell Carcinoma Antigen Recognized by T cells 1) is a human protein encoded by the *SART1* gene, located on chromosome 11q13. It plays dual roles in cellular processes: as a nuclear RNA-binding protein involved in pre-mRNA splicing and as a tumor-associated antigen implicated in cancer immunology. SART1 exists in two isoforms: SART1(259), primarily localized in the nucleus, and SART1(825), found in the cytoplasm. The latter has garnered significant interest due to its overexpression in various cancers, particularly squamous cell carcinomas (e.g., esophageal, lung, and head/neck cancers), where it serves as a target for cytotoxic T lymphocytes (CTLs).
Recombinant SART1 protein is engineered through genetic cloning and expression systems (e.g., *E. coli* or mammalian cells) to study its immunogenic properties and molecular interactions. Its cytoplasmic isoform contains CTL-recognized epitopes presented by HLA class I molecules, making it a candidate for cancer vaccine development. Research focuses on leveraging recombinant SART1 to enhance antitumor immune responses, validate diagnostic biomarkers, and elucidate its paradoxical roles in RNA processing versus tumorigenesis. Ongoing studies also explore its potential as a therapeutic target, given its involvement in cell cycle regulation and apoptosis resistance in malignant cells.
×
